Samarium-153Sm-EDTMP as an equivalent variant to pharmaceutical analgesic treatment.
J BUON
; 19(4): 1083-91, 2014.
Article
em En
| MEDLINE
| ID: mdl-25536620
ABSTRACT
PURPOSE:
Cancer pain is the most serious symptom for patients, especially during their terminal phase, when palliative medicine is needed. Our study tried to verify the usefulness of single-shot intravenous administration of Samarium (Sm)-153EDTMP in patients with bone metastases (group-A, N=53, males=25, females=28, age range 30-69 years), as well as to compare a series of variables, using as a control group (group-B, N=37, males=17, females=20, age range 30-69 years) with patients who were under drug treatment given from a physician specialized in palliative medicine.METHODS:
Both groups answered the following questionnaires Greek Brief Pain Inventory (GBPI), Brief Multidimensional Life Satisfaction Scale (BMLSS), Hospital Anxiety Depression Scale (HADS) and ECOG performance status.RESULTS:
Pain severity and pain interference improvement p=0.0005 for both groups. HADS-anxiety Samarium group, p= 0.397, drugs group p= 0.031. HADS-depression improvement for both groups p=0.031 and p=0.003, respectively. BMLSS improvement p=0.029 and p=0.265, while EGOG PS improvement was p=0.005 and p=0.014, respectively (numeric values).CONCLUSION:
Intravenous administration of Sm-153EDTMP was equivalent to drug treatment against cancer pain for patients with multiple bone metastasis, an option for those patients who are intolerant or resistant to drug treatment. Samarium-treated patients needed less or not at all pain killers, having a better cost-effective result.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Compostos Organometálicos
/
Compostos Organofosforados
/
Dor
/
Neoplasias Ósseas
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Grécia